Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis

Trial Profile

Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2017 Results of proteomic analysis of sera collected from two phase II trial including this published in The Journal of Rheumatology
    • 05 Dec 2015 New trial record
    • 01 Jan 2015 Status changed from active, no longer recruiting to completed according to results published in the Arthritis and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top